Back to results
US 12,397,048 B2Granted
Bunyavirales vaccine
AssigneeCureVac AG
InventorsBenjamin Petsch, Edith Jasny
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCureVac AG
InventorsBenjamin Petsch, Edith Jasny
Estimating the term…
The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA, and to polypeptides suitable for use in treatment or prophylaxis of an infection with a virus of the order Bunyavirales, particularly Severe fever with thrombocytopenia syndrome virus (SFTSV), Rift Valley fever virus (RVFV), or Crimean-Congo hemorrhagic fever virus (CCHFV), or a disorder related to such an infection. The present invention further concerns a Bunyavirales vaccine, particularly a SFTSV, RVFV, or CCHFV vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.
A purified RNA comprising at least one coding sequence encoding at least one antigenic polypeptide derived from a Crimean-Congo hemorrhagic fever virus (CCHFV) Glycoprotein Gc, wherein the at least one antigenic polypeptide comprises an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.